Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 302 results

LSIPR 50 2017: Raj Panjabi


Raj Panjabi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

Counterfeit drugs: protecting lives and IP

Brazil, Mexico01-11-2017

Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat.

The PTAB’s biggest test yet


With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out.

Patent extension in Canada: Making up for lost time


Following the signing of a historic trade agreement with the EU, Canada now has a system of patent term extension. LSIPR considers the impact for pharmaceutical patentees.

Raising the plausibility bar

EU26-10-2017David Carling and Richard Wells

Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.

Bridging the great divide

Brazil24-10-2017Samantha Salim and Kene Gallois

Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications.

Plausibility: How much information is enough?

EU24-10-2017Iain Armstrong

Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.

After Brexit: new directions for clinical trials

UK10-10-2017Rachel Bradley

If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

Data analysis: the highs and lows of generic-filed IPRs

US30-08-2017Wenhua Yu, Stephen Maebius and Tianran Yan

Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner.

The innovation paradox: why complex drug research is not being rewarded

EU, US12-07-2017

The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law.

Showing 81 to 90 of 302 results